title: Arginine deprivation, autophagy, apoptosis (AAA) for the treatment of melanoma.
abstract: The majority of melanoma cells do not express argininosuccinate synthetase (ASS), and hence cannot synthesize arginine from citrulline. Their growth and proliferation depend on exogenous supply of arginine. Arginine degradation using arginine deiminase (ADI) leads to growth inhibition and eventually cell death while normal cell which express ASS can survive. This notion has been translated into clinical trial. Pegylated ADI (ADI-PEG20) has shown antitumor activity in melanoma. However, the sensitivity to ADI is different among ASS(-) melanoma cells. We have investigated and reviewed the signaling pathways which are affected by arginine deprivation and their consequences which lead to cell death. We have found that arginine deprivation inhibits mTOR signaling but leads to activation of MEK and ERK with no changes in BRAF. These changes most likely lead to autophagy, a possible mechanism to survive by recycling intracellular arginine. However apoptosis does occur which can be both caspase dependent or independent In order to increase the therapeutic efficacy of this form of treatment, one should consider adding other agent(s) which can drive the cells toward apoptosis or inhibit the autophagic process.
authors.affiliation: VA Medical Center, Miami, FL 33125, USA. nsavaraj@med.miami.edu
authors.forename: N
authors.initials: N
authors.lastname: Savaraj
authors.forename: M
authors.initials: M
authors.lastname: You
authors.forename: C
authors.initials: C
authors.lastname: Wu
authors.forename: M
authors.initials: M
authors.lastname: Wangpaichitr
authors.forename: M T
authors.initials: MT
authors.lastname: Kuo
authors.forename: L G
authors.initials: LG
authors.lastname: Feun
mesh_terms: D017209:Apoptosis / Q000502:physiology; D001120:Arginine / Q000037:antagonists & inhibitors* / Q000378:metabolism; D001124:Argininosuccinate Synthase / Q000378:metabolism; D001343:Autophagy / Q000502:physiology; D006801:Humans; D006867:Hydrolases / Q000627:therapeutic use; D047908:Intracellular Signaling Peptides and Proteins / Q000378:metabolism; D020935:MAP Kinase Signaling System; D008545:Melanoma / Q000378:metabolism / Q000473:pathology / Q000628:therapy*; D008954:Models, Biological; D011092:Polyethylene Glycols / Q000627:therapeutic use; D017346:Protein Serine-Threonine Kinases / Q000378:metabolism; D015398:Signal Transduction; D058570:TOR Serine-Threonine Kinases
chemical_list: D047908:Intracellular Signaling Peptides and Proteins; D011092:Polyethylene Glycols; D001120:Arginine; C546842:MTOR protein, human; D017346:Protein Serine-Threonine Kinases; D058570:TOR Serine-Threonine Kinases; D006867:Hydrolases; C512527:ADI PEG20; D001124:Argininosuccinate Synthase
references.citation: J Biol Chem. 2009 Aug 7;284(32):21412-24
references.pmid: 19520853
references.citation: Cell Death Differ. 2005 Nov;12 Suppl 2:1509-18
references.pmid: 16247498
references.citation: Pathol Oncol Res. 2002;8(1):18-25
references.pmid: 11994758
references.citation: Cell Death Differ. 2009 Jan;16(1):12-20
references.pmid: 18600232
references.citation: Leukemia. 2000 May;14(5):826-9
references.pmid: 10803513
references.citation: Eur J Biochem. 2003 May;270(9):1887-99
references.pmid: 12709047
references.citation: J Biol Chem. 2008 Feb 22;283(8):4766-77
references.pmid: 18073215
references.citation: Biochem Biophys Res Commun. 2004 Jan 9;313(2):429-36
references.pmid: 14684180
references.citation: Nat Cell Biol. 2004 Dec;6(12):1221-8
references.pmid: 15558033
references.citation: Nature. 1968 Aug 17;219(5155):750-2
references.pmid: 5667076
references.citation: J Biol Chem. 2003 May 9;278(19):16667-74
references.pmid: 12609989
references.citation: Pathobiology. 2001;69(3):120-6
references.pmid: 11872957
references.citation: Curr Pharm Des. 2008;14(11):1049-57
references.pmid: 18473854
references.citation: Int J Cancer. 1992 May 8;51(2):244-9
references.pmid: 1568792
references.citation: Curr Opin Oncol. 2008 Mar;20(2):183-9
references.pmid: 18300768
references.citation: Nat Rev Cancer. 2005 Sep;5(9):726-34
references.pmid: 16148885
references.citation: Expert Opin Investig Drugs. 2006 Jul;15(7):815-22
references.pmid: 16787144
references.citation: Biochem Biophys Res Commun. 2004 Jan 9;313(2):443-6
references.pmid: 14684182
references.citation: J Biol Chem. 2008 Apr 18;283(16):10892-903
references.pmid: 18281291
references.citation: Infect Immun. 1990 Aug;58(8):2510-5
references.pmid: 2370103
references.citation: Autophagy. 2009 May;5(4):567-8
references.pmid: 19276647
references.citation: J Gastroenterol Hepatol. 2007 Jan;22(1):86-91
references.pmid: 17201887
references.citation: J Cell Sci. 2000 Apr;113 ( Pt 7):1189-98
references.pmid: 10704370
references.citation: Am J Clin Nutr. 2006 Feb;83(2):508S-512S
references.pmid: 16470022
references.citation: Cell Res. 2007 Oct;17(10):839-49
references.pmid: 17893711
references.citation: Curr Opin Cell Biol. 2005 Dec;17(6):596-603
references.pmid: 16226444
references.citation: Biochem Biophys Res Commun. 2010 Apr 9;394(3):760-6
references.pmid: 20227389
references.citation: Biochimie. 2008 Feb;90(2):313-23
references.pmid: 17928127
references.citation: Proc Soc Exp Biol Med. 1966 Dec;123(3):790-5
references.pmid: 5959021
references.citation: Drug Target Insights. 2007;2:119-28
references.pmid: 21901069
references.citation: Jpn J Cancer Res. 1995 Sep;86(9):840-6
references.pmid: 7591961
references.citation: Cancer Res. 2009 Jan 15;69(2):700-8
references.pmid: 19147587
references.citation: J Clin Oncol. 2005 Oct 20;23(30):7660-8
references.pmid: 16234528
references.citation: Genes Cells. 2008 Jun;13(6):537-47
references.pmid: 18533003
references.citation: Clin Cancer Res. 2006 Dec 1;12(23):7126-31
references.pmid: 17145837
references.citation: Cancer Genet Cytogenet. 2004 Jan 1;148(1):1-6
references.pmid: 14697634
references.citation: Cancer Res. 1990 Aug 1;50(15):4522-7
references.pmid: 2164440
references.citation: Nat Rev Mol Cell Biol. 2007 Sep;8(9):741-52
references.pmid: 17717517
references.citation: Proc Natl Acad Sci U S A. 2004 Mar 9;101(10):3438-43
references.pmid: 14993595
references.citation: Cancer Res. 2007 Jan 1;67(1):309-17
references.pmid: 17210712
references.citation: Cell Death Differ. 2004 Apr;11(4):448-57
references.pmid: 14713959
references.citation: Autophagy. 2007 Jan-Feb;3(1):28-31
references.pmid: 16969128
references.citation: Med Sci Monit. 2002 Jul;8(7):BR248-53
references.pmid: 12118186
references.citation: Cancer Res. 1990 Jan 15;50(2):345-9
references.pmid: 2403840
references.citation: Mol Cancer Ther. 2009 Dec;8(12):3223-33
references.pmid: 19934275
references.citation: Nat Cell Biol. 2007 Oct;9(10):1102-9
references.pmid: 17909521
references.citation: Cancer Res. 2002 Oct 1;62(19):5443-50
references.pmid: 12359751
references.citation: J Nutr. 2004 Oct;134(10 Suppl):2837S-2841S; discussion 2853S
references.pmid: 15465796
references.citation: Mol Cell Biochem. 2003 Feb;244(1-2):177-85
references.pmid: 12701828
references.citation: Autophagy. 2007 Jul-Aug;3(4):381-3
references.pmid: 17457036
references.citation: Cell. 2005 Jan 28;120(2):237-48
references.pmid: 15680329
references.citation: Cancer Lett. 2009 May 8;277(1):91-100
references.pmid: 19138817
references.citation: J Clin Invest. 2005 Oct;115(10):2679-88
references.pmid: 16200202
references.citation: J Clin Oncol. 2004 May 15;22(10):1815-22
references.pmid: 15143074
references.citation: Leuk Res. 1990;14(10):931-4
references.pmid: 2259230
references.citation: J Clin Invest. 2007 Feb;117(2):326-36
references.pmid: 17235397
references.citation: J Biol Chem. 2005 Aug 12;280(32):29060-6
references.pmid: 15980064
references.citation: Hepatogastroenterology. 2003 Sep-Oct;50(53):1214-6
references.pmid: 14571701
references.citation: Semin Cancer Biol. 2005 Aug;15(4):247-53
references.pmid: 15886013
references.citation: Annu Rev Nutr. 2005;25:59-85
references.pmid: 16011459